Psychotherapeutics: Antidepressants, Antipsychotics, Antianxiety Drugs, World Market

 
   Single User - $995
   Corporate License - $7,000


Loading...
Published Jan 1, 2007 | 292 Pages | Pub ID: KLI1340128

The market for psychotherapeutics drugs is about to change dramatically -- and serious pharmaceutical market watchers will want to be prepared. Kalorama’s Psychotherapeutics: Antidepressants, Antipsychotics, Antianxiety Drugs: World Market is the most exhaustive guide available to this booming market and the direction it is headed in the next four years.

Psychotherapeutics treat conditions classified as abnormal behavior, thoughts and feelings that persist for a determined amount of time causing distress or emotional/physical impairment. Depression, anxiety, psychosis, ADHD and nicotine and drug dependence are among the conditions psychotherapeutics treat. Well-known brands such as Prozac™, Zoloft™ and Ritalin ™ have made this a $37 billion market. And according to Kalorama’s research, revenues from this area will grow more than 50% by 2010.

Antidepressants, Antipsychotics, Antianxiety Drugs, and other Psychotherapeutics: World Marketcovers this market completly including an overview; surveys of the key corporate players, geographic market breakdowns, and revenue forecasts to 2010 in these key market segments:

  • Antidepressants
  • Antipsychotics/Antimanics
  • Antianxiety Drugs
  • Stimulants and Non-stimulants for ADHD
  • Smoking Cessation Drugs, Drug Addiction Treatments, Eating Disorder Treatments and Other Psychotherapeutics

In every category of psychotherapeutics, new competitors are emerging. Kalorama’s report provides profiles of thirty-six new psychotherapeutic drugs in the pipeline, their expected approval status, and how they may shake up the marketplace - as well as a complete discussion of the issues and trends that will effect psychotherapeutics.

The report also includes current issues and trends affecting the industry including the increasing number of additional indications pharma companies are seeking for their brands and success stories in this area.

Over 110 tables and figures clearly demonstrate the current and future psychotherapeutic markets.

As part of our complete coverage, the following companies are profiled:

  • Astellas Pharma, Inc.
  • AstraZeneca Plc
  • Biovail Corporation
  • Bristol-Myers Squibb
  • Eli Lilly & Company
  • Forest Laboratories, Inc.
  • GlaxoSmithKline Plc
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Otsuka Pharmaceutical Co. Ltd.
  • Pfizer, Inc.
  • Shire Pharmaceuticals Group Plc
  • Wyeth

Kalorama’s trusted information-gathering process provides the most accurate study of the market for anti-depressants, anti-anxiety drugs, ADHD treatments and other psychotherapeutic drugs available today. Information and analysis presented in this report is based on extensive interviews with senior management of top companies and in the psychotherapeutics market. While financial reports, major research literature and government information is culled, information is corroborated and key market insights originate from interviews with industry leaders.

Product managers, marketing managers, business development executives, advertising agency or investment firm executives, as well as information and research center librarians are among the individuals who will find this survey of the changing psychotherapeutics market essential.

Kalorama’s Antidepressants, Antipsychotics, Antianxiety Drugs, and other Psychotherapeutics: World Market provides coverage of the following brands:

  • Nardil
  • Parnate
  • Prozac
  • Paxil
  • Zoloft
  • Celexa
  • Lexapro
  • Effexor and Effexor XR
  • Cymbalta
  • Wellbutrin and Wellbutrin XL and Wellbutrin SR
  • Serzone
  • Desyrel
  • Remeron
  • Symbyax
  • Tolvon
  • Xanax
  • Ativan
  • Klonopin
  • Valium
  • Versed
  • BuSpar
  • Lexotan
  • Paxil/Seroxat and Paxil CR
  • Zoloft
  • Ritalin
  • Focalin and Focalin XR
  • Daytrana
  • Strattera
  • Concerta
  • Metadate CD
  • Adderall and Adderall XR
  • Chantix/Champix
  • Zyban
  • Accomplia
  • Nicotrol
  • Subutex
  • Campral
  • Methodone
  • ReVia/Naltrex
  • Antabuse
  • Narcan
  • Vivitrol
  • Depade
  • YAZ
  • SSRIs
  • Compazine, Serentil, Stelazine, Thorazine
  • Geodon
  • Zyprexa
  • Risperdal, Risperdal Consta
  • Clozaril
  • Seroquel
  • Abilify
  • Lithobid, Eskalith
  • Symbyax
  • Lamictal
  • EMSAM
Chapter One: Executive Summary
  • Introduction
  • Scope and Methodology
  • Size and Growth of the Market
  • Issues and Trends Affecting Market
  • Competitive Summary
  • Company Profiles

Chapter Two: Introduction

  • Conditions
    • Depressive Disorders
    • Depression
    • Seasonal Affective Disorder
    • Psychotic Disorders
    • Bipolar Disorder
    • Schizophrenia
    • Anxiety Disorders
    • Attention Deficit Disorders
    • Eating Disorders
    • Addiction Disorders

  • Condition Statistics
    • Depression
    • Dysthymic Disorder
    • Seasonal Affective Disorder (SAD)
    • Bipolar Disorder
    • Psychomotor Agitation
    • Tourette Syndrome
    • Schizophrenia
    • Generalized Anxiety Disorder
    • Social Anxiety Disorder
    • Obsessive Compulsive Disorder
    • Panic Disorder
    • Post Traumatic Stress Disorder
    • Phobias
    • Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD)
    • Nicotine, Alcohol, and Drug Addiction
    • Bulimia/Anorexia
    • Premenstrual Dysphoric Disorder

  • History and Growth of the Psychotherapeutic Drug Market
  • Industry Structure and Product Segments

chapter Three: Antidepressants

  • Overview
  • Description of Depression
    • Epidemiology of Depression
    • Economic Impact of Depression

  • Description of Products
    • Monoamine Oxidase Inhibitors
      • Nardil
      • Parnate

    • Selective Serotonin Reuptake Inhibitors
      • Prozac/Sarafem
      • Paxil/Seroxat and Paxil CR
      • Zoloft
      • Celexa
      • Lexapro

    • Serotonin and Norepinephrine Reuptake Inhibitors
      • Effexor and Effexor XR
      • Cymbalta

    • Aminoketones
      • Wellbutrin and Wellbutrin XL and Wellbutrin SR

    • Phenylpiperazines
      • Serzone
      • Desyrel

    • Tetracyclics and Miscellaneous
      • Remeron
      • Symbyax
      • Tolvon
      • EMSAM

  • Products in Research and Development
    • Desvenlafaxine succinate
    • Gepirone ER
    • Vilazodone
    • Seroquel SR
    • Saredutant (SR 48968)
    • SR 58611
    • DOV 216,303
    • Corlux
    • Valdoxan

  • Market Size and Growth
    • Total World Market
    • Markets by Geographical Segments
      • U.S. Market
      • European Union Market
      • Japan Market
      • ROW Market

    • Market Data by Indication

  • Competitive Analysis

chapter Four: Antipsychotics and Antimanics

  • Overview
    • Description of Conditions
      • Schizophrenia
      • Bipolar Disorder
      • Tourette’s Syndrome

    • Epidemiology
    • Economic Impact

  • Description of Products
    • Phenothiazines
      • Compazine, Serentil, Stelazine, Thorazine
      • Geodon

    • Thienobenzodiazepines
      • Zyprexa

    • Benzisoxazole Derivatives
      • Risperdal, Risperdal Consta

    • Dibenzodiazepine and Dibenzothiazepine Derivatives
      • Clozaril
      • Seroquel

    • Dopamine Partial Agonist
      • Abilify

    • Lithium
      • Lithobid, Eskalith

    • Miscellaneous
      • Symbyax
      • Lamictal

    • Research and Development
      • Paliperidone, Paliperidone ER, Paliperidone Palmitate IM
      • Asenapine
      • Bifeprunox
      • Lamictal
      • Iloperidone (Zomaril)
      • LIC 477D
      • Seroquel SR

    • Market Size and Growth
      • Total World Market
      • Markets by Geographical Segments
        • U.S. Market
        • European Union Market
        • Japan Market
        • ROW Market

      • Market Data by Indication

    • Competitive Analysis

chapter Five: Antianxiety Drugs

  • Overview
    • Description of Conditions
    • Economic Impact

  • Description of Products
    • Benzodiazipines
      • Xanax
      • Ativan
      • Klonopin
      • Valium
      • Versed

    • Miscellaneous Antianxiety Agents
      • BuSpar
      • Lexotan
      • Prozac/Sarafem
      • Paxil/Seroxat and Paxil CR
      • Zoloft
      • Effexor and Effexor XR

    • Research and Development
      • Cipralex
      • Cymbalta
      • Lyrica
      • Desvenlafaxine succinate
      • DOV 216,303
      • PDX 00023
      • Gepirone ER
      • Saredutant (SR 48968)
      • SR 58611
      • Valdoxan

    • Market Size and Growth
      • Total World Market
      • Markets by Geographical Segments
        • U.S. Market
        • European Union Market
        • Japan Market
        • ROW Market

      • Market Data by Indication

    • Competitive Analysis

CHAPTER SIX: CNS Stimulants and Nonstimulant Attention Deficit Hyperactive Disorder Treatments

  • Overview
    • Description of Conditions
    • Economic Impact

  • Description of Products
    • Amphetamines
      • Ritalin
      • Focalin and Focalin XR
      • Daytrana

    • Selective Norepinephrine Reuptake Inhibitors
      • Strattera

    • Central Nervous System Stimulants
      • Concerta
      • Metadate CD

    • Sympathomimetic Amines
      • Adderall and Adderall XR

    • Research and Development
      • NRP104/LDX
      • Guanfacine ER (SPD-503)
      • SPD-465

    • Market Size and Growth
      • Total World Market
      • Markets by Geographical Segments
        • U.S. Market
        • European Union Market
        • Japan Market
        • ROW Market

      • Competitive Analysis

chapter Seven: Other Psychotherapeutic Drugs

  • Overview
    • Description of Conditions
      • Eating Disorders - Anorexia and Bulimia
      • Substance Abuse - Alcohol, Narcotic, Nicotine
      • Premenstrual Dysphoric Disorder

    • Economic Impact

  • Description of Products
    • Smoking Cessation
      • Chantix/Champix
      • Zyban
      • Accomplia
      • Nicotrol

    • Alcohol and Opiate Dependence and Related
      • Subutex
      • Campral
      • Methodone
      • ReVia/Naltrex
      • Antabuse
      • Narcan
      • Vivitrol
      • Depade

    • Bulimia/Anorexia
      • Prozac

    • Premenstrual Dysophoric Syndrome
      • YAZ
      • SSRIs

  • Research and Development
    • Acomplia
    • Lofexidine
    • Naltrexone Depot
    • Lybrel
    • SSR591813
    • Cyt002-NicQb
    • NicVAX

  • Market Size and Growth
    • Total World Market
    • Markets by Geographical Segments
      • U.S. Market
      • European Union Market
      • Japan and ROW Market

    • Market Data by Indication

  • Competitive Analysis

Chapter Eight: Issues and Trends Affecting the Psychotherapeutic Drug Market

  • introduction
    • Patent Expiration Tactics
    • Smoking Cessation and Genetic Testing
    • New Drug Targets
    • ADHD Drugs
    • Caring Across Communities Program
    • Prescription Drug Abuse
    • Drug Advertising and Promotion

Chapter Nine: The Evolving Psychotherapeutic

  • Drug Market:
  • Market Forecasts
    • Overview
    • Total market Size and Forecast
    • Competitor Analysis

chapter TeN: Company Profiles

  • Introduction
  • Competitive Summary
  • Astellas Pharma, Inc.
  • AstraZeneca Plc
  • Biovail Corporation
  • Bristol-Myers Squibb
  • Eli Lilly & Company
  • Forest Laboratories, Inc.
  • GlaxoSmithKline Plc
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Otsuka Pharmaceutical Co. Ltd.
  • Pfizer, Inc.
  • Shire Pharmaceuticals Group Plc
  • Wyeth

Appendix
Company Directory

List of Exhibits

Chapter One: Executive Summary

  • Table 1-1: Market Summary: Total World Psychotherapeutic
  • Drug Market 2003-2010 Figure 1-1: Trending in the World Market for Psychotherapeutic Drugs 2003-2010

Chapter TWO: INTRODUCTION

  • Table 2-1: Estimated World and U.S. Prevalence of Psychotic Conditions
  • or Disorders
  • Figure 2-1: Estimated World Prevalence of Psychotic Conditions or Disorders
  • Figure 2-2: Estimated U.S. Prevalence of Psychotic Conditions or Disorders

Chapter THREE: ANTIDEPRESSANTS

  • Table 3-1: Estimated World and U.S. Prevalence of Depression
  • Figure 3-1: Estimated World and U.S. Prevalence of Depression
  • Table 3-2: Recent FDA Antidepressant Approvals, 2003-2006 (Product, Generic Name, Manufacturer/Marketer, Approval Date, Patent Expiration Date)
  • Table 3-3: Antidepressants in Research and Development (Product, Developer, Indication, Phase)
  • Table 3-4: The World Market for Antidepressant Drugs 2003-2010
  • Figure 3-2: Trending in the World Market for Antidepressant Drugs, 2003-2010
  • Table 3-5: The World Market for Antidepressant Drugs by Product Classification (SSRIs, S/NRIs, Others) 2003-2010
  • Figure 3-3: Trending in the World Market for Antidepressant Drugs by Product Class, 2003-2010
  • Figure 3-4: Revenue Distribution by Product Class in the World Market for Antidepressant Drugs, 2003-2010
  • Table 3-6: The World Market for Antidepressant Drugs by Geographical Segment (U.S., European Union, Japan, ROW) 2003-2010
  • Figure 3-5: Trending in the Regional Markets for Antidepressant 2003-2010
  • Table 3-7: Estimated Antidepressant Sales by Indication (Depression and Major Depressive Disorder vs Seasonal Affective Disorder), 2005
  • Table 3-8: The World Market for Antidepressant Drugs Revenues and Market Share of Leading Suppliers Esitmated 2005 and Projected 2010
  • Figure 3-6: Leading Suppliers’ Shares of the World Antidepressant Drug Market 2005
  • Figure 3-7: Leading Suppliers’ Shares of the World Antidepressant Drug Market 2010
  • Table 3-9: Estimated Sales and Market Share of Top Antidepressant Drugs 2005
  • Figure 3-8: Leading Products’ Shares of the World Antidepressant Drug Market 2005

Chapter FOUR: ANTIPSYCHOTICS AND ANTIMANICS

  • Table 4-1: Estimated World and U.S. Prevalence of Psychotic and Manic Disorders
  • Figure 4-1: Estimated World and U.S. Prevalence of Psychotic and Manic Disorders
  • Table 4-2: Recent FDA Antipsychotic/Antimanic Approvals, 2003-2006 (Product, Generic Name, Manufacturer/Marketer, Approval Date, Patent Expiration Date)
  • Table 4-3: Antipsychotics and Antimanics in Research and Development (Product, Developer, Indication, Phase)
  • Table 4-4: World Market : Antipsychotic and Antimanic Drugs, 2003-2010
  • Figure 4-2: World Market Antipsychotic and Antimanic Drugs, 2003-2010
  • Table 4-5:: World Market: Antipsychotic and Antimanic Drugs by Product Classification, 2003-2010
  • Figure 4-3: World Market Antipsychotic and Antimanic Drugs by Product Classification Revenues, 2003-2010
  • Figure 4-4 World Market: Antipsychotic and Antimanic Drugs by Product Classification and Percent Distribution, 2003-2010
  • Figure 4-5 : World Market Antipsychotic and Antimanic Drugs by Product Classification and Percent Market Share, 2005
  • Figure 4-6: World Market and Antimanic Drugs by Product Classification and Percent Market Share, 2010
  • Table 4-6: World Market Antipsychotic and Antimanic Drug Market by Geographical Segment, 2003-2010 Figure 4-7: World Market Antipsychotic and Antimanic Drug Market by
  • Geographical Segment, 2003-2010
  • Figure 4-8 World Market Antipsychotic and Antimanic Drug Market by Geographical Segment Percent Distribution, 2003-2010
  • Figure 4-9 World Market Antipsychotic and Antimanic Drug Market by Geographical Segment and Percent Market Share, 2005
  • Figure 4-10: World Market Antipsychotic and Antimanic Drug Market by Geographical Segment and Percent Market Share, 2010
  • Table 4-7: Estimated Antipsychotic and Antimanic Drug Sales by Indication, 2005
  • Figure 4-11 Estimated Antipsychotic and Antimanic Drug Sales by Indication, 2005
  • Table 4-8: World Market : Antipsychotic and Antimanic Drug: Leading Suppliers Shares by Market Revenues, Estimated 2005 and Projected 2010
  • Figure 4-12: World Market: Antipsychotic and Antimanic Drugs Leading Suppliers Market Share, Estimated 2005
  • Table 4-9: Antipsychotic and Antimanic Drug Market, 2003-2010; Top Antipsychotic and Antimanic Drugs by Estimated Sales and Percent of Market, 2005
  • Figure 4-13: Antipsychotic and Antimanic Drug Market, 2003-2010 ; Top Antipsychotic and Antimanic Drugs by Estimated Sales and Percent of Market, 2005

Chapter FIVE: ANTIANXIETY DRUGS

  • Table 5-1: Estimated World and U.S. Prevalence of Conditions
  • Figure 5-1: Estimated World and U.S. Prevalence of Conditions
  • Table 5-2: Research and Development: Antianxiety Drugs
  • Table 5-3: World Market Antianxiety Drugs, 2003-2010
  • Figure 5-2: World Market Antianxiety Drugs, 2003-2010
  • Table 5-4: World Market: Drugs by Product Classification, 2003-2010
  • Figure 5-3 World Market Antianxiety Drugs by Product Classification Revenues, 2003-2010
  • Figure 5-4 World Market Antianxiety Drugs by Product Classification and Percent Distribution, 2003-2010
  • Table 5-5: Antianxiety Drugs by Product Classification and Percent Distribution, 2003-2010
  • Figure 5-5 Antianxiety Drugs by Product Classification and Percent Market Share, 2005
  • Figure 5-6 World Market: Antianxiety Drugs by Product Classification and Percent Market Share, 2010
  • Table 5-5: World Market: Antianxiety Drug Market by Geographical Segment, 2003-2010
  • Figure 5-7: World Market Antianxiety Drug Market by Geographical Segment, 2003-2010
  • Figure 5-8: World Market: Drug Market by Geographical Segment Percent Distribution, 2003-2010
  • Figure 5-9: World Market Antianxiety Drug Market by Geographical Segment and Percent Market Share, 2005
  • Figure 5-10: Market Drug Market by Geographical Segment and Percent Market Share, 2010
  • Table 5-6: Estimated Antianxiety Drug Sales by Indication, 2005
  • Figure 5-11: Antianxiety Drug Sales by Indication, 2005
  • Table 5-7: World Market: Antianxiety Drugs: Leading Suppliers Shares by Market Revenues, Estimated 2005 and Projected 2010
  • Figure 5-12: Market Antianxiety Drugs Leading Suppliers Market Share, Estimated 2005
  • Figure 5-13: World Market Antianxiety Drugs: Suppliers Market Share, Projected 2010 Table 5-8: Antianxiety Drug Market, 2003-2010 Top Antianxiety Drugs by Estimated Sales and Percent of Market, 2005
  • Figure 5-14: Drug Market, 2003-2010 Top Antianxiety Drugs by Estimated Sales and Percent of Market, 2005

Chapter SIX: CNS STIMULANTS AND NONSTIMULANT ATTENTION DEFICIT HYPERACTIVE DISORDER TREATMENTS

  • Table 6-1: Estimated World and U.S. Prevalence of Conditions
  • Figure 6-1: Estimated World and U.S. Prevalence of Conditions
  • Table 6-2: Recent Stimulant Approvals, 2003-2006
  • Table 6-3: Research and Development: Stimulants
  • Table 6-4 World Market Stimulants and Non-Stimulants in the ADHD Market, 2003-2010
  • Figure 6-2: World Market: Stimulants and Non-Stimulants in the ADHD Market, 2003-2010
  • Table 6-5: World Market: Stimulants and Non-Stimulants in the ADHD Market by Geographical Segment, 2003-2010
  • Figure 6-3: World Market: Stimulants and Non-Stimulants in the ADHD Market by Geographical Segment, 2003-2010
  • Figure 6-4: World Market: Stimulants and Non-Stimulants in the ADHD Market by Geographical Segment Percent Distribution, 2003-2010
  • Figure 6-5: World Market : Stimulants and Non-Stimulants in the ADHD Market by Geographical Segment and Percent Market Share, 2005
  • Figure 6-6: World Market: Stimulants and Non-Stimulants in the ADHD Market by Geographical Segment and Percent Market Share, 2010
  • Table 6-6: World Market: Stimulants and Non-Stimulants in ADHD Treatment Leading Suppliers Shares by Market Revenues,
  • Figure 6-7: World Market: Stimulants and Non-Stimulants in ADHD Treatment
  • Figure 6-8: World Market: Stimulants and Non-Stimulants in ADHD Treatment
  • Table 6-7: Stimulants and Non-Stimulants in the ADHD Market, 2003-2010
  • Figure 6-9: Stimulants and Non-Stimulants in the ADHD Market, 2003-2010

CHAPTER SEVEN: OTHER PSYCHOTHERAPEUTIC DRUGS

  • Table 7-1: Estimated World Prevalence of Conditions
  • Figure 7-1: Estimated World Prevalence of Conditions
  • Table 7-2: Recent Other Psychotherapeutic Drug Approvals
  • Table 7-3: and Development: Other Psychotherapeutic Drugs
  • Figure 7-2: Research and Development: Other Psychotherapeutic Drugs
  • Table 7-4: World Market: Other Psychotherapeutic Drugs, 2003-2010
  • Figure 7-2: World Market: Other Psychotherapeutic Drugs, 2003-2010
  • Table 7-5: World Market:Other Psychotherapeutic Drugs by Product Classification, 2003-2010
  • Figure 7-3: Other Psychotherapeutic Drugs by Product Classification Revenues,
  • Figure 7-4: Other Psychotherapeutic Drugs by Product Classification and Percent Distribution,
  • Figure 7-5: Other Psychotherapeutic Drugs by Product Classification and Percent Market Share, 2005
  • Figure 7-6: Other Psychotherapeutic Drugs by Product Classification and Percent Market Share, 2010
  • Table 7-6: Other Psychotherapeutic Drug Market by Geographical Segment
  • Figure 7-7: World Market:Other Psychotherapeutic Drug Market by Geographical Segment, 2003-2010
  • Figure 7-8 Segment Percent Distribution, 2003-2010
  • Figure 7-9: Market: Psychotherapeutic Drug Market by Geographical Segment and Percent Market Share, 2005
  • Figure 7-10: World Market: Other Psychotherapeutic Drug Market by Geographical Segment and Percent Market Share, 2010
  • Table 7-5: Estimated Other Psychotherapeutic Drug Sales by Indication, 2005 (in million of dollars at the manufacturers level)
  • Figure 7-11: Estimated Other Psychotherapeutic Drug Sales by Indication, 2005
  • Table 7-7: World Market Other Psychotherapeutic Drugs Leading Suppliers Shares by Market Revenues, Estimated 2005 and Projected 2010
  • Figure 7-12: World Market Other Psychotherapeutic Drugs Leading Suppliers Market Share, Estimated 2005
  • Figure 7-13: World Market Other Psychotherapeutic Drugs Leading Suppliers Market Share, Projected 2010
  • Table 7-8: Psychotherapeutic Drug Market, 2003-2010 Top Drugs by Estimated Sales and Percent of Market, 2005 (in million of dollars at the manufacturers level)
  • Figure 7-14: Other Psychotherapeutic Drug Market, 2003-2010 Top Drugs by Estimated Sales and Percent of Market, 2005

CHAPTER EIGHT: ISSUES AND TRENDS AFFECTING THE PSYCHOTHERAPEUTIC DRUG MARKET

  • Table 8-1: Patent Data

CHAPTER NINE: THE EVOLVING PSYCHOTHERAPEUTIC DRUG MARKET

  • Table 9-1: Psychotherapeutic Drug Market, 2003-2010
  • Figure 9-1: Psychotherapeutic Drug Market, 2003-2010
  • Figure 9-2: Psychotherapeutic Drug Market by Percent and Treatment Segment, 2005
  • Figure 9-3: Psychotherapeutic Drug Market by Percent and Treatment Segment, 2010
  • Table 9-2: Leading Suppliers, Products, and Segments of Participation 2005
  • Figure 9-4: Leading Suppliers Market Shares 2005

In this report, {{keyword[keywordTextProperty]}} appears {{keyword[keywordCountProperty]}} times. {{searchResults.STATRESULT.SUMMARY.KW[keywordTextProperty]}} appears {{searchResults.STATRESULT.SUMMARY.KW[keywordCountProperty]}} times.

We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.